Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirusZaid Taha(University of Ottawa), Jean‐Simon Diallo(University of Ottawa)Frontiers in ImmunologyApril 19, 202310.3389/fimmu.2023.1181014Cited by 11SaveCiteExport RISWatch citationsRelated PapersPevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy|Molecular Therapy|2023|23The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy|Communications Biology|2020|16Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy|Nature Communications|2024|14